List of Ayvakit drug patents

Ayvakit is owned by Blueprint Medicines.

Ayvakit contains Avapritinib.

Ayvakit has a total of 3 drug patents out of which 0 drug patents have expired.

Ayvakit was authorised for market use on 09 January, 2020.

Ayvakit is available in tablet;oral dosage forms.

Ayvakit can be used as treatment of unresectable or metastatic gastrointestinal stromal tumor (gist) harboring a platelet-derived growth factor receptor alpha (pdgfra) exon 18 mutation; treatment of advanced systemic mastocytosis, including patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with an associated hematological neoplasm (sm-ahn), and mast cell leukemia (mcl).

Drug patent challenges can be filed against Ayvakit from January, 2024.

The generics of Ayvakit are possible to be released after 15 October, 2034.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9944651 BLUEPRINT MEDICINES Compositions useful for treating disorders related to kit
Oct, 2034

(11 years from now)

US9994575 BLUEPRINT MEDICINES Compositions useful for treating disorders related to kit
Oct, 2034

(11 years from now)

US9200002 BLUEPRINT MEDICINES Compositions useful for treating disorders related to KIT
Oct, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 9, 2025
New Indication (I) Jun 16, 2024
Orphan Drug Exclusivity (ODE) Jan 9, 2027

Drugs and Companies using AVAPRITINIB ingredient

NCE-1 date: January, 2024

Market Authorisation Date: 09 January, 2020

Treatment: Treatment of unresectable or metastatic gastrointestinal stromal tumor (gist) harboring a platelet-derived growth factor receptor alpha (pdgfra) exon 18 mutation; Treatment of advanced systemic mastocytosis, including patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with an associated hematological neoplasm (sm-ahn), and mast cell leukemia (mcl)

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in